LONZA GROUP AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 293.9 EUR | +1.48% |
|
-.--% | -.--% |
| 05-14 | Swiss Market Index Edges Up Ahead of Inflation Report | MT |
| 05-14 | Global markets live: Apple, Sony, Vodafone, Booking, Walmart... |  |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 43.4 and 34.64 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -.--% | 42.49B | - | ||
| +33.40% | 49.46B | B- | ||
| +1.63% | 42.58B | B | ||
| -4.22% | 29.09B | C | ||
| +11.60% | 26.61B | B- | ||
| -22.78% | 18.64B | B | ||
| +8.09% | 13.16B | B+ | ||
| +29.19% | 12.55B | C+ | ||
| +24.33% | 12.1B | B+ | ||
| -4.67% | 11.98B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LONN Stock
- LO3 Stock
- Ratings Lonza Group AG
